Results 1 to 10 of about 5,564 (117)

Comparison of meglumine antimoniate versus miltefosine in the treatment of new world cutaneous leishmaniasis: a systematic review and meta-analysis [PDF]

Anais Brasileiros de Dermatologia
Background Cutaneous leishmaniasis (CL) affects up to 1.2 million people annually, mainly in resource-limited regions. Meglumine antimoniate, the standard treatment, is limited by systemic toxicity, injectable administration, and increasing resistance ...
Ana Carolina Putini Vieira, Fernanda Cronemberger Lins, Arianne Costa Baquião   +2 more
doaj   +3 more sources

Antiparasitic properties of miltefosine-based nanoformulations against protozoan pathogen, Acanthamoeba castellanii

Advances in Biomedical and Health Sciences, 2022
Background: Acanthamoeba castellanii genotype T4 is the causative agent of the progressively increasing sight-threatening Acanthamoeba keratitis and central nervous system infections.
Noor Akbar, Roberta Cagliani, Jibran Sualeh Muhammad, Mutasem Rawas-Qalaji, Balsam Qubais Saeed, Naveed Ahmed Khan, Ruqaiyyah Siddiqui   +6 more
doaj   +1 more source

Impavido attenuates inflammation, reduces atherosclerosis, and alters gut microbiota in hyperlipidemic mice

iScience, 2023
Summary: Impavido (Miltefosine) is an FDA-approved drug for treating leishmaniasis and primary amebic meningoencephalitis. We have shown previously that Miltefosine increased cholesterol release and dampened Nlrp3 inflammasome assembly in macrophages ...
C. Alicia Traughber, Amanda J. Iacano, Kalash Neupane, Mariam R. Khan, Emmanuel Opoku, Tina Nunn, Ashutosh Prince, Naseer Sangwan, Stanley L. Hazen, Jonathan D. Smith, Kailash Gulshan   +10 more
doaj   +1 more source

In Vitro Susceptibility to Miltefosine of Leishmania infantum (syn. L. chagasi) Isolates from Different Geographical Areas in Brazil

Microorganisms, 2021
Treatment of visceral leishmaniasis in Brazil still relies on meglumine antimoniate, with less than ideal efficacy and safety, making new therapeutic tools an urgent need.
Caroline Ricce Espada, Erica V. de Castro Levatti, Mariana Côrtes Boité, Dorcas Lamounier, Jorge Alvar, Elisa Cupolillo, Carlos Henrique Nery Costa, Joelle Rode, Silvia R. B. Uliana   +8 more
doaj   +1 more source

In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis. [PDF]

PLoS Neglected Tropical Diseases, 2014
Miltefosine was the first oral compound approved for visceral leishmaniasis chemotherapy, and its efficacy against Leishmania donovani has been well documented.
Adriano C Coelho, Cristiana T Trinconi, Carlos H N Costa, Silvia R B Uliana   +3 more
doaj   +1 more source

3′Nucleotidase/nuclease is required for Leishmania infantum clinical isolate susceptibility to miltefosineResearch in context

EBioMedicine, 2022
Summary: Background: Miltefosine treatment failure in visceral leishmaniasis in Brazil has been associated with deletion of the miltefosine susceptibility locus (MSL) in Leishmania infantum.
Juliana B.T. Carnielli, Anuja Dave, Audrey Romano, Sarah Forrester, Pedro R. de Faria, Renata Monti-Rocha, Carlos H.N. Costa, Reynaldo Dietze, Ian A. Graham, Jeremy C. Mottram   +9 more
doaj   +1 more source

Miltefosine Suppresses Hepatic Steatosis by Activating AMPK Signal Pathway. [PDF]

PLoS ONE, 2016
BACKGROUND AND PURPOSE:It has been accepted that AMPK (Adenosine monophosphate-activated protein kinase) activation exhibits many beneficial effects on glucolipid metabolism.
Ru Fang, Xudong Zhu, Yaqin Zhu, Xing Tong, Kexue Li, Hui Bai, Xiaoyu Li, Jingjing Ben, Hanwen Zhang, Qing Yang, Qi Chen   +10 more
doaj   +1 more source

Miltefosine Against Scedosporium and Lomentospora Species: Antifungal Activity and Its Effects on Fungal Cells

Frontiers in Cellular and Infection Microbiology, 2021
Scedosporium and Lomentospora species are filamentous fungi responsible for a wide range of infections in humans and are frequently associated with cystic fibrosis and immunocompromising conditions.
Rodrigo Rollin-Pinheiro, Yuri de Castro Almeida, Victor Pereira Rochetti, Mariana Ingrid Dutra da Silva Xisto, Luana Pereira Borba-Santos, Sonia Rozental, Eliana Barreto-Bergter   +6 more
doaj   +1 more source

Antifungal Activity and Mode of Action of Miltefosine Against Clinical Isolates of Candida krusei

Frontiers in Microbiology, 2020
Candida krusei attracts attention from medical professionals mainly for its intrinsic resistance to fluconazole and the limited number of drugs available to treat C. krusei vulvovaginal candidiasis.
Yongqin Wu, Mengying Wu, Jing Gao, Chunmei Ying   +3 more
doaj   +1 more source

Screening of Chemical Libraries for New Antifungal Drugs against Aspergillus fumigatus Reveals Sphingolipids Are Involved in the Mechanism of Action of Miltefosine

mBio, 2021
Aspergillus fumigatus is an important fungal pathogen and the main etiological agent of aspergillosis, a disease characterized by a noninvasive process that can evolve to a more severe clinical manifestation, called invasive pulmonary aspergillosis (IPA),
Thaila Fernanda dos Reis, Maria Augusta Crivelente Horta, Ana Cristina Colabardini, Caroline Mota Fernandes, Lilian Pereira Silva, Rafael Wesley Bastos, Maria Vitória de Lazari Fonseca, Fang Wang, Celso Martins, Márcio L. Rodrigues, Cristina Silva Pereira, Maurizio Del Poeta, Koon Ho Wong, Gustavo H. Goldman   +13 more
doaj   +1 more source